Product
Indication
In Vitro Confirmationof Lead Candidate
Efficacy Study in Animal Model
Candidate Confirmation
Pre-clinical
Clinical
Bispecific Antibody
BAB-05
Hematological malignancies
IND expected in 2026-Q4
TCI-312
Prostate Cancer
Pre-clinical
AF-29
Rare disease/Acute gouty arthritis
IND expected in 2026-Q4
lCM-053
Solid/Hematological cancer
Pre-clinical
Antibody Conjugates
TCI-212
NACLC
Pre-clinical---IND expected in 2026-Q4
BTA-024
Prostate Cancer
Candidate Confirmation